A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Sirolimus

abstract

  • Temsirolimus was generally well tolerated on this intermittent schedule. Encouraging preliminary antitumor activity was observed.

publication date

  • October 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-0118

PubMed ID

  • 17020981

Additional Document Info

start page

  • 5755

end page

  • 63

volume

  • 12

number

  • 19